195 related articles for article (PubMed ID: 20481650)
1. Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen.
Kasserra C; Sansone-Parsons A; Keung A; Tetteh E; Assaf M; O'Mara E; Marbury T
Clin Pharmacokinet; 2010 Jun; 49(6):397-406. PubMed ID: 20481650
[TBL] [Abstract][Full Text] [Related]
2. Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
Kasserra C; Li J; March B; O'Mara E
Clin Ther; 2011 Oct; 33(10):1503-14. PubMed ID: 22015327
[TBL] [Abstract][Full Text] [Related]
3. Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.
O'Mara E; Kasserra C; Huddlestone JR; Wan Y; Soni P; Caceres M; Medlock M; Morrison R; Devinsky O
Antimicrob Agents Chemother; 2010 Jun; 54(6):2448-54. PubMed ID: 20350942
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials.
Kasserra C; O'Mara E
Clin Pharmacokinet; 2011 Apr; 50(4):267-80. PubMed ID: 21348539
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
[TBL] [Abstract][Full Text] [Related]
6. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.
Sekar V; Lefebvre E; De Marez T; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
Clin Drug Investig; 2008; 28(8):479-85. PubMed ID: 18598093
[TBL] [Abstract][Full Text] [Related]
7. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S; Russell D; Taylor-Worth RJ; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):27-37. PubMed ID: 18333863
[TBL] [Abstract][Full Text] [Related]
8. Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable.
Fätkenheuer G; Hoffmann C; Slim J; Rouzier R; Keung A; Li J; Treitel M; Sansone-Parsons A; Kasserra C; O'Mara E; Schürmann D
J Acquir Immune Defic Syndr; 2010 Jan; 53(1):78-85. PubMed ID: 19838130
[TBL] [Abstract][Full Text] [Related]
9. Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.
Suleiman J; Zingman BS; Diaz RS; Madruga JV; DeJesus E; Slim J; Mak C; Lee E; McCarthy MC; Dunkle LM; Walmsley S
J Infect Dis; 2010 Feb; 201(4):590-9. PubMed ID: 20064072
[TBL] [Abstract][Full Text] [Related]
10. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
[TBL] [Abstract][Full Text] [Related]
11. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.
Schürmann D; Fätkenheuer G; Reynes J; Michelet C; Raffi F; van Lier J; Caceres M; Keung A; Sansone-Parsons A; Dunkle LM; Hoffmann C
AIDS; 2007 Jun; 21(10):1293-9. PubMed ID: 17545705
[TBL] [Abstract][Full Text] [Related]
12. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
13. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
Emmelkamp JM; Rockstroh JK
Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
[TBL] [Abstract][Full Text] [Related]
14. Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir.
Kaeser B; Zandt H; Bour F; Zwanziger E; Schmitt C; Zhang X
Antimicrob Agents Chemother; 2009 Feb; 53(2):609-14. PubMed ID: 19015329
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).
Crawford KW; Li C; Keung A; Su Z; Hughes MD; Greaves W; Kuritzkes D; Gulick R; Flexner C;
J Acquir Immune Defic Syndr; 2010 Apr; 53(5):598-605. PubMed ID: 20071999
[TBL] [Abstract][Full Text] [Related]
16. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects.
Liu P; Foster G; Gandelman K; LaBadie RR; Allison MJ; Gutierrez MJ; Sharma A
Antimicrob Agents Chemother; 2007 Oct; 51(10):3617-26. PubMed ID: 17646413
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.
Gulick RM; Su Z; Flexner C; Hughes MD; Skolnik PR; Wilkin TJ; Gross R; Krambrink A; Coakley E; Greaves WL; Zolopa A; Reichman R; Godfrey C; Hirsch M; Kuritzkes DR;
J Infect Dis; 2007 Jul; 196(2):304-12. PubMed ID: 17570119
[TBL] [Abstract][Full Text] [Related]
18. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
[TBL] [Abstract][Full Text] [Related]
19. Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.
Wilkin TJ; Su Z; Krambrink A; Long J; Greaves W; Gross R; Hughes MD; Flexner C; Skolnik PR; Coakley E; Godfrey C; Hirsch M; Kuritzkes DR; Gulick RM
J Acquir Immune Defic Syndr; 2010 Aug; 54(5):470-6. PubMed ID: 20672447
[TBL] [Abstract][Full Text] [Related]
20. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
